DALY II USA/ MB-CART2019.1 for DLBCL

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(25 sites)

United States

Banner MD Anderson Cancer Center, Gilbert, Arizona

Mayo Clinic, Phoenix, Arizona

UC San Diego Health, La Jolla, California

Stanford University, Stanford, California

Yale University, New Haven, Connecticut

Baptist Health Miami Cancer Institute, Miami, Florida

Winship Cancer Institute of Emory University, Atlanta, Georgia

Georgia Cancer Center at Augusta University, Augusta, Georgia

Robert H Lurie Cancer Center, Chicago, Illinois

University of Kansas Cancer Center, Westwood, Kansas

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

University of Michigan, Ann Arbor, Michigan

Mayo Clinic, Rochester, Minnesota

University of Nebraska Medical Center, Omaha, Nebraska

Memorial Sloan Kettering Cancer Center, New York, New York

Duke University Medical Center - Division of Hematologic Malignancies, Durham, North Carolina

The Ohio State University Wexner Medical Center James Cancer, Columbus, Ohio

Oregon Health and Science University Knight Cancer Institute, Portland, Oregon

Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania

University of Pittsburgh - Hillman Cancer Center, Pittsburgh, Pennsylvania

UT Southwestern Medical Center, Dallas, Texas

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin

Canada

University of Alberta Cross Cancer Institute, Edmonton, Alberta

Princess Margaret Cancer Centre, Toronto, Ontario